Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2007 / Cilt: 33 - Sayı: 1

Erectile dysfunction in patients with Parkinson disease

Parkinson hastalarında cinsel işlev bozukluğu

Pages
36–39
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that there was a statistically significant correlation between severity of Parkinson disease and severity of ED (p<0.0001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Erectile dysfunction (ED) is a disorder in which a male is not able to provide and/or maintain enough erection during sexual intercourse for duration of at least 6 months.
📊
Key Findings & Data:Parkinson disease is a neurodegenerative disorder which is clinically identified with motor symptoms, tremor, rigidity and bradikinesia occurring after loss of approximately 70% of dopaminergic neurons in substantia nigra and it gives response to dopamin replacement treatment.
💡
Conclusion & Impact:It was found that there was a statistically significant correlation between severity of Parkinson disease and severity of ED (p<0.0001).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Parkinson hastalığı · Erektil disfonksiyon · Yaşam kalitesi

Abstract

Introduction: Erectile dysfunction (ED) is a disorder in which a male is not able to provide and/or maintain enough erection during sexual intercourse for duration of at least 6 months. Parkinson disease is a neurodegenerative disorder which is clinically identified with motor symptoms, tremor, rigidity and bradikinesia occurring after loss of approximately 70% of dopaminergic neurons in substantia nigra and it gives response to dopamin replacement treatment. Materials and Methods: Severities of Parkinson disease and ED were measured using UPDRS (Unified Parkinson&#8217;s disease Rating Scale) scoring and IIEF-5 scoring, respectively. The patients were evaluated by Beck&#8217;s Depression Scale and those patients who were in depression and who had comorbidities (i.e. cerebrovascular diseases, cardiovascular diseases and Diabetes Mellitus) that might causes ED were excluded from study. Thirty (30) patients with Parkinson disease who were 55-78 (mean: 65.26±6.06) years old were included into study. Pearson&#8217;s test of correlation analysis was used for statistical evaluation. A p<0.05 was regarded to be statistically significant. Results: UPDRS scores and IIEF-5 scores were between 40 and 65 (mean: 50.86±8.93) and between 7 and 17 (mean: 11.06±3.16), respectively. There was no statistically significant correlation between age and IIEF-5 scores (p: 0.17). There was also no statistically significant correlation between age and severity of Parkinson disease (p: 0.19). It was found that there was a statistically significant correlation between severity of Parkinson disease and severity of ED (p<0.0001). Conclusion: ED is an important problem which causes worsening in quality of life in patients with Parkinson disease. Our study confirmed that as severity of disease in patients with Parkinson disease was increased, severity of ED was also increased and quality of life was worsened.

Özet

Erektil disfonksiyon (ED), bir erkeğin en az 6 ay süre ile cinsel ilişki için yeterli ereksiyonu sağlayamaması ve/ veya sürdürememesi durumudur. Parkinson hastalığı, substantia nigrada dopamin oluşturan nöronların yaklaşık %70'inin kaybı sonucu beliren motor belirtiler, titreme, rijidite ve bradikinezi ile klinik olarak tanımlanan ve dopamin replasman tedavisine yanıt veren nörodejeneratif bir bozukluktur. Parkinson hastalığı tanısı almış hastalarda UPDRS (Unified Parkinson’s Disease Rating Scale) skorlaması ile Parkinson hastalığının şiddeti ve IIEF-5 ile erektil disfonksiyonun derecesi ölçüldü. Hastalar, Beck Depresyon Ölçeği ile değerlendirilip depresyon hastası olduğu tespit edilenler ve erektil disfonksiyona sebep olabilecek başka bir hastalığı olanlar (serebrovasküler hastalıklar, kardiyovasküler hastalıklar, şeker hastalığı) çalışma dışı bırakıldı. Yaşları 55-78 arasında (ortalama: 65,26±6,06) değişen 30 Parkinson hastası çalışmaya alındı. İstatistiksel değerlendirmede Pearson korelasyon analiz testi uygulandı. p<0.05 istatistiksel olarak anlamlı kabul edildi. Hastaların, UPDRS skoru ile Parkinson hastalığı ve IIEF-5 skoru ile ED dereceleri değerlendirildi. UPDRS skorları 40-65 arasında (ortalama: 50,86±8,93) ve IIEF-5 skorları 7 ile 17 arasında (ortalama: 11,06±3,16) idi. Yapılan istatistiksel değerlendirmede yaş ile IIEF-5 skorları arasında anlamlı ilişki olmadığı saptandı (p: 0,17). Yaş ile Parkinson hastalığının derecesi arasında istatistiksel olarak anlamlı ilişki yoktu (p: 0,19). Parkinson hastalığının şiddeti ile ED’nin şiddeti arasında istatistiksel olarak anlamlı ilişki bulundu (p<0,0001). ED, Parkinsonlu hastaların yaşam kalitesinin bozulmasına neden olan önemli bir sorundur. Çalışmamız, Parkinsonlu hastalarda hastalık derecesi arttıkça ED derecesinin de arttığını ve yaşam kalitesinin daha fazla bozulduğunu doğrulamaktadır.

🔖

Cite This Article

GÜRBÜZ, N., KARABAĞ, S., ARAS, B., AKTAŞ, F., KALFAZADE, N., TAŞÇI, A. İ. (2007). Erectile dysfunction in patients with Parkinson disease. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 33 - Sayı: 1, 36–39. https://ajindex.com/articles/328321

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Rosen R, Altwein J, Boyle P, et al: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol; 44: 637- 649, 2003
  2. Papatsoris AG, Triantaflylidis A, and Gekas A: Prevalence of erectile dysfunction in the European Union. Asian J Androl; 5: 255, 2003
  3. Feldman HA, Goldstein I, Hatzichristou DG, et al: Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol; 151: 54-61, 1994
  4. Hatzichristou DG: Sildenafil citrate: Lessons learned from 3 years of clinical experience. Int J Impot Res; 14 (suppl-1): 43-52, 2002
  5. Fearnly JM, Lees AJ: Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain; 114: 2283- 2301, 1991
  6. Basson R: Sexuality and Parkinson’s disease. Parkinsonism Relat Disord. 2: 177-185, 1996
  7. Welsh M, Hung L, Waters CH: Sexuality in women with Parkinson’s disease. Mov Dis; 12: 923-927, 1997
  8. Papapetropoulos S and Mash DC: Psychotic symptoms in Parkinson’s disease: From description to etiology. J Neurol; 252: 753-764, 2005
  9. Braune S, Reinhardt M, Bathmann J, et al: Impaired cardiac uptake of Parkinson’s disease with autonomic failure. Acta Neurol Scand; 97: 307-314, 1998
  10. Nehra A and Moreland RB: Neurologic erectile dysfunction. Urol Clin North Am 28: 289-308, 2001
  11. Wakabayashi K and Takahasbi H: Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol; 38 (suppl-2): 2-7, 1997
  12. Holstege JC, Van Dijken H, Buijs RM, et al: Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal kord. J Comp Neurol; 376: 631-652, 1996
  13. Van Dijken H, Dijk J, Voom P, et al: Localization of dopamine D2 receptor in rat spinal cord identified with immunochemistry and in situ hybridization. Eur Neurosci; 8: 621-628, 1996
  14. Zarrindast MR, Shokravi S and Samini M: Opposite influences of dopaminergic receptor subtypes on penile erection. Gen Pharmacol; 23: 671-675, 1992
  15. Hoenh MM and Yahr MD: Parkinsonism: Onset, progression and mortality. Neurology; 17: 427-442, 1967
  16. Bronner G, Royter V, Korczyn AD, et al: Sexual dysfunction in Parkinson’s disease. J Sex Marital Ther; 30: 95-104, 2004
  17. Hobson B, Islam W, Roberts S, et al: The risk of bladder and autonomic dysfunction in a community cohort Parkinson’s disease patients and normal controls. Parkinsonism Relat Disord; 10: 67-71, 2003
  18. Singer C, Weiner WJ, Sanchez-Ramos JR, et al: Sexual dysfunction in me